This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332

The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder

There are currently 25 open trials. In 117 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 25 open trials

Step 3: View Details

Trial Title:

Oxford pre-cancerous disorders study (OxPLoreD)



Myeloma stage:

Smouldering, MGUS

Trial phase:



This study aims to uncover new biological markers which help identify patients who are more likely to develop myeloma by observing and monitoring patients with non-cancerous disorders, MGUS (monoclonal gammopathies of undetermined significance), Waldenstroms Macroglobulinaemia (WM) and Smouldering Myeloma (SM).



Churchill Hospital, Oxford

Who can enter the study?

Who can enter the study?:

Patients with IgM, IgA or IgG MGUS, smouldering myeloma or non-symptomatic Waldenstrom’s Macroglobulinaemia who have been diagnosed in the last two years.

What's involved?

What's involved?:

Patients will be studied for up to 5 years.

Patients will be required to:

  • Provide blood, bone marrow and saliva samples at key time-points.
  • Answer questions or complete questionnaires about what it is like to live with one of these conditions
Clinical Information

Clinical Information
(for Medical Professionals):

This observational study to identify clinical, genomic and immunological predictive markers of progression to malignant disease. The study is open to patients diagnosed in the last 2 years with early-stage Chronic Lymphocytic Leukaemia (CLL), Monoclonal B-cell Lymphocytosis (MBL), Monoclonal Gammopathy of Uncertain Significance (MGUS), asymptomatic Waldenstroms Macroglobulinaemia (WM) and Smouldering Myeloma (SM). For more information, click here.


Find out more about Myeloma UK:


Do you want to talk to someone? Call our myeloma Infoline